Research graph
References from The Impact of Emerging Therapies and Declining Physician Reimbursement on Dupuytren Disease Treatment: A 21 Year Review. Local targets link to admitted publications; unresolved targets remain external evidence.
Prevalence of Dupuytren disease in the Netherlands
10.1097/prs.0b013e3182958a33 · 2013 · External reference
The worldwide prevalence of the Dupuytren disease: a comprehensive systematic review and meta-analysis
10.1186/s13018-020-01999-7 · 2020 · External reference
Dupuytren’s contracture; a new concept of the pathogenesis correlated with surgical management
10.2106/00004623-195941040-00008 · 1959 · External reference
Percutaneous needle fasciotomy for Dupuytren contracture
10.2106/jbjs.st.18.00047 · 2019 · External reference
Results of needle aponeurotomy for Dupuytren contracture in over 1,000 fingers
10.1016/j.jhsa.2012.01.029 · 2012 · External reference
Injectable collagenase clostridium histolyticum for Dupuytren’s contracture
10.1056/nejmoa0810866 · 2009 · External reference
Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s disease
10.1016/j.jhsa.2010.08.007 · 2010 · External reference
Five-year results of a randomized, controlled trial of collagenase treatment compared with needle fasciotomy for Dupuytren contracture
10.1016/j.jhsa.2021.11.019 · 2022 · External reference
Injectable collagenase versus percutaneous needle fasciotomy for Dupuytren contracture in proximal interphalangeal joints: a randomized controlled trial
10.1016/j.jhsa.2017.03.003 · 2017 · External reference
Collagenase clostridium histolyticum in Dupuytren’s contracture: a systematic review
10.1093/bmb/ldw020 · 2016 · External reference
Surgical complications associated with fasciectomy for Dupuytren’s disease: a 20-year review of the English literature
2010 · External reference
Safety and tolerability of collagenase Clostridium histolyticum and fasciectomy for Dupuytren’s contracture
10.1177/1753193414528843 · 2015 · External reference
Factors influencing recurrence and progression of Dupuytren’s disease treated by collagenase Clostridium histolitycum
10.1007/s00264-017-3690-0 · 2018 · External reference
A 10-year review of collagenase versus fasciectomy in the treatment of Dupuytren contracture
2024 · External reference
Long-term assessment of collagenase treatment for Dupuytren’s contracture: a 10-year follow-up study
10.5312/wjo.v15.i4.355 · 2024 · External reference
Dupuytren’s contracture recurrence and treatment following collagenase clostridium histolyticum injection: a longitudinal assessment in a Veteran population
10.1093/milmed/usad075 · 2023 · External reference
Dupuytren contracture recurrence following treatment with collagenase Clostridium histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study]): 5-Year data
10.1016/j.jhsa.2015.04.036 · 2015 · External reference
In treatment-naïve Dupuytren contracture, surgery had a higher success rate at 2 years than needle fasciotomy or collagenase injection
10.2106/jbjs.24.01104 · 2024 · External reference
Collagenase injections for Dupuytren’s disease: prospective cohort study assessing 2-year treatment effect durability
10.1136/bmjopen-2016-012943 · 2017 · External reference
Percutaneous needle fasciotomy versus collagenase injection for Dupuytren’s contracture: a systematic review of comparative studies
10.1055/s-0040-1721876 · 2021 · External reference
Percutaneous needle fasciotomy versus collagenase treatment for Dupuytren contracture: a randomized controlled trial with a two-year follow-up
10.2106/jbjs.17.01128 · 2018 · External reference
Comparison of treatment outcome after collagenase and needle fasciotomy for Dupuytren contracture: a randomized, single-blinded, clinical trial with a 1-year follow-up
10.1016/j.jhsa.2016.06.014 · 2016 · External reference
Collagenase treatment versus needle fasciotomy for single-digit Dupuytren contractures: a meta-analysis of randomized controlled trials
10.1016/j.jhsa.2023.08.008 · 2023 · External reference
Cost-effectiveness of recurrent Dupuytren contracture treatment
10.1001/jamanetworkopen.2020.19861 · 2020 · External reference
Cost-effectiveness of open partial fasciectomy, needle aponeurotomy, and collagenase injection for Dupuytren contracture
10.1016/j.jhsa.2011.08.004 · 2011 · External reference
Collagenase clostridium histolyticum for the treatment of Dupuytren’s contracture: systematic review and economic evaluation
10.3310/hta19900 · 2015 · External reference
Cost-effectiveness in the management of Dupuytren’s contracture. A Canadian cost-utility analysis of current and future management strategies
10.1302/0301-620x.95b8.31822 · 2013 · External reference
Outcomes and direct costs of needle aponeurotomy, collagenase injection, and fasciectomy in the treatment of Dupuytren contracture
10.1016/j.jhsa.2019.07.017 · 2019 · External reference
Google trend analysis shows increasing public interest in platelet-rich plasma injections for hip and knee osteoarthritis
10.1016/j.arth.2021.05.040 · 2021 · External reference
Science and the sources of hype
10.1159/000336533 · 2012 · External reference
Inflation-adjusted Medicare reimbursement has decreased for orthopaedic sports medicine procedures: analysis from 2000 to 2020
10.1177/23259671211073722 · 2022 · External reference
Temporal analysis of Medicare physician reimbursement and procedural volume for all hip and knee arthroplasty procedures billed to Medicare part B from 2000 to 2019
10.1016/j.arth.2021.02.006 · 2021 · External reference
Declining Medicare reimbursement for urologists: an opportunity for informed advocacy
10.1097/ju.0000000000001655 · 2021 · External reference
An analysis of procedural Medicare reimbursement rates in hand surgery: 2000 to 2019
10.1177/1558944721990807 · 2022 · External reference
Declining trend in Medicare physician reimbursements for hand surgery from 2002 to 2018
10.1016/j.jhsa.2020.08.010 · 2020 · External reference
Temporal and geographic trends in Medicare reimbursement of primary and revision shoulder arthroplasty: 2000 to 2020
10.5435/jaaos-d-20-01369 · 2021 · External reference
Medicare reimbursement in hand and upper extremity procedures: a 20-year analysis
10.1177/15589447221096708 · 2024 · External reference
In the shadow of a giant: Medicare’s influence on private physician payments
10.1086/689772 · 2017 · External reference
Dupuytren disease: prevalence, incidence, and lifetime risk of surgical intervention. A population-based cohort analysis
10.1097/prs.0000000000009919 · 2023 · External reference
Dupuytren’s disease risk factors
10.1016/j.jhsb.2004.06.006 · 2004 · External reference
Cost-effectiveness of recurrent Dupuytren contracture treatment
10.1001/jamanetworkopen.2020.19861 · ExternalCitation · doi-reference
Factors influencing recurrence and progression of Dupuytren’s disease treated by collagenase Clostridium histolitycum
10.1007/s00264-017-3690-0 · ExternalCitation · doi-reference
Temporal analysis of Medicare physician reimbursement and procedural volume for all hip and knee arthroplasty procedures billed to Medicare part B from 2000 to 2019
10.1016/j.arth.2021.02.006 · ExternalCitation · doi-reference
Google trend analysis shows increasing public interest in platelet-rich plasma injections for hip and knee osteoarthritis
10.1016/j.arth.2021.05.040 · ExternalCitation · doi-reference
Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s disease
10.1016/j.jhsa.2010.08.007 · ExternalCitation · doi-reference
Cost-effectiveness of open partial fasciectomy, needle aponeurotomy, and collagenase injection for Dupuytren contracture
10.1016/j.jhsa.2011.08.004 · ExternalCitation · doi-reference
Results of needle aponeurotomy for Dupuytren contracture in over 1,000 fingers
10.1016/j.jhsa.2012.01.029 · ExternalCitation · doi-reference
Dupuytren contracture recurrence following treatment with collagenase Clostridium histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study]): 5-Year data
10.1016/j.jhsa.2015.04.036 · ExternalCitation · doi-reference
Comparison of treatment outcome after collagenase and needle fasciotomy for Dupuytren contracture: a randomized, single-blinded, clinical trial with a 1-year follow-up
10.1016/j.jhsa.2016.06.014 · ExternalCitation · doi-reference
Injectable collagenase versus percutaneous needle fasciotomy for Dupuytren contracture in proximal interphalangeal joints: a randomized controlled trial
10.1016/j.jhsa.2017.03.003 · ExternalCitation · doi-reference
Outcomes and direct costs of needle aponeurotomy, collagenase injection, and fasciectomy in the treatment of Dupuytren contracture
10.1016/j.jhsa.2019.07.017 · ExternalCitation · doi-reference
Declining trend in Medicare physician reimbursements for hand surgery from 2002 to 2018
10.1016/j.jhsa.2020.08.010 · ExternalCitation · doi-reference
Five-year results of a randomized, controlled trial of collagenase treatment compared with needle fasciotomy for Dupuytren contracture
10.1016/j.jhsa.2021.11.019 · ExternalCitation · doi-reference
Collagenase treatment versus needle fasciotomy for single-digit Dupuytren contractures: a meta-analysis of randomized controlled trials
10.1016/j.jhsa.2023.08.008 · ExternalCitation · doi-reference
Dupuytren’s disease risk factors
10.1016/j.jhsb.2004.06.006 · ExternalCitation · doi-reference
Percutaneous needle fasciotomy versus collagenase injection for Dupuytren’s contracture: a systematic review of comparative studies
10.1055/s-0040-1721876 · ExternalCitation · doi-reference
Injectable collagenase clostridium histolyticum for Dupuytren’s contracture
10.1056/nejmoa0810866 · ExternalCitation · doi-reference
In the shadow of a giant: Medicare’s influence on private physician payments
10.1086/689772 · ExternalCitation · doi-reference
Collagenase clostridium histolyticum in Dupuytren’s contracture: a systematic review
10.1093/bmb/ldw020 · ExternalCitation · doi-reference
Dupuytren’s contracture recurrence and treatment following collagenase clostridium histolyticum injection: a longitudinal assessment in a Veteran population
10.1093/milmed/usad075 · ExternalCitation · doi-reference
Declining Medicare reimbursement for urologists: an opportunity for informed advocacy
10.1097/ju.0000000000001655 · ExternalCitation · doi-reference
Dupuytren disease: prevalence, incidence, and lifetime risk of surgical intervention. A population-based cohort analysis
10.1097/prs.0000000000009919 · ExternalCitation · doi-reference
Prevalence of Dupuytren disease in the Netherlands
10.1097/prs.0b013e3182958a33 · ExternalCitation · doi-reference
Collagenase injections for Dupuytren’s disease: prospective cohort study assessing 2-year treatment effect durability
10.1136/bmjopen-2016-012943 · ExternalCitation · doi-reference
Science and the sources of hype
10.1159/000336533 · ExternalCitation · doi-reference
An analysis of procedural Medicare reimbursement rates in hand surgery: 2000 to 2019
10.1177/1558944721990807 · ExternalCitation · doi-reference
Medicare reimbursement in hand and upper extremity procedures: a 20-year analysis
10.1177/15589447221096708 · ExternalCitation · doi-reference
Safety and tolerability of collagenase Clostridium histolyticum and fasciectomy for Dupuytren’s contracture
10.1177/1753193414528843 · ExternalCitation · doi-reference
Inflation-adjusted Medicare reimbursement has decreased for orthopaedic sports medicine procedures: analysis from 2000 to 2020
10.1177/23259671211073722 · ExternalCitation · doi-reference
The worldwide prevalence of the Dupuytren disease: a comprehensive systematic review and meta-analysis
10.1186/s13018-020-01999-7 · ExternalCitation · doi-reference
Cost-effectiveness in the management of Dupuytren’s contracture. A Canadian cost-utility analysis of current and future management strategies
10.1302/0301-620x.95b8.31822 · ExternalCitation · doi-reference
Dupuytren’s contracture; a new concept of the pathogenesis correlated with surgical management
10.2106/00004623-195941040-00008 · ExternalCitation · doi-reference
Percutaneous needle fasciotomy versus collagenase treatment for Dupuytren contracture: a randomized controlled trial with a two-year follow-up
10.2106/jbjs.17.01128 · ExternalCitation · doi-reference
In treatment-naïve Dupuytren contracture, surgery had a higher success rate at 2 years than needle fasciotomy or collagenase injection
10.2106/jbjs.24.01104 · ExternalCitation · doi-reference
Percutaneous needle fasciotomy for Dupuytren contracture
10.2106/jbjs.st.18.00047 · ExternalCitation · doi-reference
Collagenase clostridium histolyticum for the treatment of Dupuytren’s contracture: systematic review and economic evaluation
10.3310/hta19900 · ExternalCitation · doi-reference
Long-term assessment of collagenase treatment for Dupuytren’s contracture: a 10-year follow-up study
10.5312/wjo.v15.i4.355 · ExternalCitation · doi-reference
Temporal and geographic trends in Medicare reimbursement of primary and revision shoulder arthroplasty: 2000 to 2020
10.5435/jaaos-d-20-01369 · ExternalCitation · doi-reference
